Analysis of Lung Microbiome in COVID-19 Patients during Time of Hospitalization
Pathogens · 17.07.2023 · 12 (7) · 944
DOI: 10.3390/pathogens12070944 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pathogens, online erschienen am 17.07.2023. Verfasst von Linlin Xie und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Laboratory Medicine, Zhongnan Hospital of Wuhan University, Wuhan 430071, China. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Key Research and Development Program of China, Key Project for Anti-2019 Novel Coronavirus Pneumonia from the National Key Research and Development Program of China, National Natural Science Foundation of China.
Abstract (Originalsprache)
Background
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which is the pathogenic agent of the rapidly spreading pneumonia called coronavirus disease 2019 (COVID-19), primarily infects the respiratory and digestive tract. Several studies have indicated the alterations of the bacterial microbiome in the lower respiratory tract during viral infection. However, both bacterial and fungal microbiota in the lung of COVID-19 patients remained to be explored.
Methods
In this study, we conducted nanopore sequencing analyses of the lower respiratory tract samples from 38 COVID-19 patients and 26 non-COVID-19 pneumonia controls. Both bacterial and fungal microbiome diversities and microbiota abundances in the lung were compared.
Results
Our results revealed significant differences in lung microbiome between COVID-19 patients and non-COVID-19 controls, which were strongly associated with SARS-CoV-2 infection and clinical status. COVID-19 patients exhibited a notably higher abundance of opportunistic pathogens, particularly Acinetobacter baumannii and Candida spp. Furthermore, the potential pathogens enriched in COVID-19 patients were positively correlated with inflammation indicators.
Conclusions
Our study highlights the differences in lung microbiome diversity and composition between COVID-19 patients and non-COVID-19 patients. This may contribute to predicting co-pathogens and selecting optimal treatments for respiratory infections caused by SARS-CoV-2.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Laboratory Medicine, Zhongnan Hospital of Wuhan University, Wuhan 430071, China.
- Department of Neurosurgery, Zhongnan Hospital of Wuhan University, Wuhan 430071, China.
- Wuhan Research Center for Infectious Diseases and Tumors, Chinese Academy of Medical Sciences, Wuhan 430071, China.
- Hubei Engineering Center for Infectious Disease Prevention, Control and Treatment, Wuhan 430071, China.
ORCID-Profile: Zhiqiang Li
Förderung
- National Key Research and Development Program of China
- Key Project for Anti-2019 Novel Coronavirus Pneumonia from the National Key Research and Development Program of China
- National Natural Science Foundation of China
- Key Research and Development Program of Hubei Province
- 2021 Hubei Provincial Leading Public Health Talents Project
Zitieren
APA
Xie, L., Chen, L., Li, X., Zhou, J., Tian, H., Zhao, J., Li, Z., & Li, Y. (2023). Analysis of Lung Microbiome in COVID-19 Patients during Time of Hospitalization. Pathogens, 12(7), 944. https://doi.org/10.3390/pathogens12070944
Vancouver
Xie L, Chen L, Li X, Zhou J, Tian H, Zhao J, et al. Analysis of Lung Microbiome in COVID-19 Patients during Time of Hospitalization. Pathogens. 2023;12(7):944. doi:10.3390/pathogens12070944
BibTeX
@article{Xie2023,
author = {Xie, Linlin and Chen, Liangjun and Li, Xinran and Zhou, Junying and Tian, Hongpan and Zhao, Jin and Li, Zhiqiang and Li, Yirong},
title = {Analysis of Lung Microbiome in COVID-19 Patients during Time of Hospitalization},
journal = {Pathogens},
year = {2023},
volume = {12},
number = {7},
pages = {944},
doi = {10.3390/pathogens12070944}
}
EUVIMED